Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer...
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on...